Despite the preliminary designation, YICHANG HUMANWELL’s anticipated FDA approval for the generic version of this unspecified therapeutic, targeted for September 25, 2026, is expected to generate significant market share gains upon launch. This development positions the company as a major competitor in the segment once the product gains accessibility.